Treatment Information

Back

Non-Hodgkin's Lymphoma treatment details. Chemotherapy, Hormone, Biologic therapy.

Kyungpook National University Hospital, Jung-Gu, Daegu, Korea.

Survival: monthsCountry:Korea
Toxiciy Grade:5City/State/Province:Jung-Gu, Daegu
Treatments:Chemotherapy, Hormone, Biologic therapyHospital:Kyungpook National University Hospital
Drugs:Journal:Link
Date:Jun 2007

Description:

Patients:
This phase 2 study involved 20 peripheral T-cell lymphoma patients. The median patient age was 50.5 years and 14 were male.

Treatment:
Patients were treated with the chemotherapy agents cyclophosphamide, doxorubicin, and vincristine, the hormone prednisone, and the biologic therapy agent alemtuzumab (an antibody against the CD52 protein that helps the immune system attack cancer cells).

Toxicities:
Treatment-related deaths due to pneumonia and sudden death were reported. At least 90% of the patients experienced grade 4 neutropenia, leucopenia, and/or thrombocytopenia. Nausea, vomiting, and constipation were also reported.

Results:
The median overall survival was 8.7 months.

Correspondence: Dr. Sang Kyun Sohn; email: [email protected]



Back